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Objective. To investigate whether patients on long-term antisecretory medication need to continue treatment to control symptoms.
Methods. A double-blinded randomised placebo-controlled trial in general practices in Denmark. Patients aged 18–90 who were
treated with antisecretory drugs on a long-term basis were randomized to esomeprazole 40mg or identical placebo. Outcome
measures were time to discontinuation with trial medication due to failed symptom control analysed as survival data. The
proportion of patients stopping trial medication during the one-year follow-up was estimated. Results. A total of 171 patients
were included with a median prior duration of antisecretory treatment of four years (range: 0.5 to 14.6 years). 86 patients received
esomeprazole 40mg and 85 patients received placebo. At 12 months, statistically significantly more patients in the placebo group
had discontinued (73% (62/85)) compared with the esomeprazole group (21% (18/86); p < 0.001). Conclusions. Long-term users of
antisecretory drugs showed a preference for the active drug compared to placebo. However, 27% of patients continued on placebo
throughout the study and did not need to reinstitute usual treatment. One in five patients treated with esomeprazole discontinued
trial medication due to unsatisfactory symptom control. Discontinuation of antisecretory treatment should be considered in long-
term users of antisecretory drugs. This trial is registered with Trial registration ClinicalTrials.gov ID: NCT00120315.
1. Introduction
The use of acid-suppressive medication is rapidly increasing.
In the western world, proton pump inhibitors (PPIs) are
second only to statins in expenditures, and antisecretory
medication constitutes a substantial part of the medical
budget in the Denmark and other western countries [1–3].
Most of the increased use of antisecretory medication is
accounted for by long-term users [4, 5].
Antisecretory medication is highly effective for the treat-
ment of peptic ulcer and reflux disease, but it has only
sparse effect in the treatment of patients with functional
dyspepsia [6]. In primary care, the most used strategy when
investigating and treating dyspeptic patients is empirical
treatment with antisecretory drugs [7]. As no data exist
regarding the optimal treatment period, and as there is
a poor correlation between initial treatment response and
continued effect, some patients might have an unnecessary
continued use of antisecretory medication [8]. In a Swedish
study, Bjo¨rnsson et al. [9] found that discontinuation of
antisecretory mediation was successful in 27% of long-term
users of PPI. Placebo-controlled discontinuation studies of
antisecretory medication with interventions carried out in
primary care are however not yet published.
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The aim of the present study was therefore in a placebo-
controlled randomised design to investigate if patients on
long-term antisecretory medication need to continue treat-
ment to control symptoms in a primary care setting.
2. Methods
2.1. Protocol. A total of 146 general practitioners in Denmark
were visited, introduced to, and educated in study procedures
and signed in as coinvestigators on the required forms
from the DanishMedicines Agency (Protocol ID: 2612-2176).
Eligible patients were evaluated, enrolled, and followed by
their general practitioner from January 2003 to September
2006.
2.2. Assignment. Patients older than 17 years with a use
of antisecretory treatment (proton pump inhibitors or
histamine-2-receptor-antagonists) for at least 56 days during
the previous six months were included. Exclusion crite-
ria were alarm symptoms (gastrointestinal bleeding, iron
deficiency anemia, progressive unintentional weight loss,
progressive dysphagia, persistent vomiting, and epigastric
mass on palpation), drug or alcohol abuse, serious or terminal
diseases, planned hospitalization during follow-up, allergy
to trial medication, and pregnant or fertile females not
using safe contraception. Furthermore, patients suffering
fromoesophagitis, having had prior complicated peptic ulcer,
and patients with prior endoscopically verified ulceration
and ongoing use of nonsteroidal anti-inflammatory drugs
(NSAIDs)/acetylic salicylic acid (ASA) were not eligible.
2.3. Interventions. Long-term users of antisecretory treat-
ment were randomised to continued antisecretory treatment
or placebo. Esomeprazole (Nexium, AstraZeneca) 40mg or
identical placebowas used as the randomised trialmedication
with a maximum of one tablet a day mimicking the patient’s
usual treatment. When trial medication was discontinued
due to insufficient symptom control, reinstitution of usual
antisecretory treatment was left to the GPs’ discretion.
2.4. Masking. Both active medication and placebo were
manufactured and packed byAstraZeneca,Mo¨lndal, Sweden,
in accordance with Good Manufactory Practice (GMP).
Trial drug was delivered in identical, sealed containers
holding 100 tablets. The local university hospital pharmacy
(Fyns Amts Centralapotek, J. B. Winsløws Vej 13, DK-5000
Odense C, Denmark) labelled and randomised the trial drug
accordingly using a computer-generated random number
block randomisation with a fixed block size of four and
a placebo/treatment ratio of one. The pharmacy kept the
sequence of allocation concealed throughout the one-year
follow-up, thus blinding patients, general practitioners, and
researchers. Following seven days of discontinuation of usual
antisecretory treatment with allowance of antacids as rescue
treatment, Helicobacter pylori status was investigated with a
13C-urea breath test performed in general practice. During
the seven days of discontinuation symptoms, demographics
and clinical baseline characteristics of participants were
obtained. Eradication therapy was given to any Helicobacter-
positive patient (amoxicillin, clarithromycin, and esomepra-
zole, alternatively metronidazole if allergic to penicillin).The
study was monitored according to Good Clinical Practice
(GCP) by the GCP unit at Odense University Hospital,
Denmark (Project number 02-004).
2.5. Outcomes. Primary endpoint was the time to discontinu-
ationwith trialmedications (esomeprazole or placebo) due to
the participants’ need to change back to their usual antisecre-
tory medication, that is, failure to control symptoms with the
trial medication at any time point in the one-year follow-up.
The proportion of patients stopping trial medication during
the one-year follow-up was estimated. Additional analysis
was carried out using health-related quality-of-life (MOS
Short Form-36) [10] and generic dyspeptic quality-of-life
(gastrointestinal symptom rating scale) [11] questionnaires.
2.6. Sample Size and Analysis. We assumed 15–20% of long-
term users to be suffering from peptic ulcer disease, 40–
45% to be suffering from nonerosive reflux disease, and
approximately 40% to be suffering from functional dyspepsia
[12]. Based on these diagnoses, we estimated the recurrence
of symptoms in 10% in the esomeprazole group and 30% in
the placebo group and given a type I error of 5% and a type II
error of 20% at least 111 patients in each group were needed.
During data analysis, patients remained in the two arms
of the study without revealing the intervention, thus allowing
a blinded data analysis of the primary endpoint [13]. Pri-
mary outcome was assessed using survival data analysis. An
intention to treat analysis was performed. Assumptions that
dropouts in both groups had insufficient control of symptoms
and therefore were analysed as having stopped with trial
medication were made.
3. Results
3.1. Participant Flow and Follow-Up. A total of 171 patients
found eligible by their general practitioners were accepted
to participate in the study (Figure 1); 17% were Helicobacter
pylori-positive. During the one-year follow-up, six patients
were lost to follow-up; no adverse events were seen, except
for one patient developing a black discoloration of the tongue
during Helicobacter pylori eradication treatment. Character-
istics at baseline are shown in Table 1. No differences were
foundbetweenGPsnot including participants comparedwith
active coinvestigators with regard to sex, single-handed or
partnership practice, and number of long-term users, data
not shown.
3.2. Analysis. At the one-year follow-up, the stop of the trial
medication had occurred more frequently (𝑝 < 0.0001,
log-rank) in the placebo group compared with the group
receiving esomeprazole. A total of 18/86 (21%) of participants
treated with esomeprazole had stopped the trial medication
compared to 62/85 (73%) of participants treated with placebo
(Figure 2). Gastrointestinal symptom scores improved in
both groups during the trial, but no statistically significant
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Figure 2: Discontinuation of trial medication in 1-year follow-up.
differences were found between the two groups after one
year (Table 2). Quality-of-life scores were unchanged, and no
differences were found between groups after one year (data
not shown).
Table 3 shows a comparison between patients contin-
uing placebo versus patients who stopped treatment with
placebo. Statistically significantly more men stopped placebo
Table 1: Demographics and clinical baseline characteristics of
participants.
Placebo PPI∗
𝑁 = 85 𝑁 = 86
Male (%) 37 (44) 41 (48)
Age, median (10%–90%
percentile), year 59 (39–79) 59 (39–77)
Smoking, 𝑛 (%; 95% CI) 31 (36; 26–48) 39 (45; 35–56)
Alcohol use, <21 units/weeks 𝑛
(%; 95% CI) 79 (93; 85–97) 79 (92; 84–97)
Symptom duration, median
(10%–90% percentile), year 4 (1–16) 4 (1–13)
Helicobacter pylori-positive 𝑛 (%;
95% CI) 12 (14; 7–23) 17 (20; 12–30)
Previous endoscopy, 𝑛 (%; 95%
CI) 46 (54; 42–64) 39 (45; 34–56)
Previous NSAID/ASA use, 𝑛 (%;
95% CI) 52 (61; 49–71) 53 (61; 50–72)
∗Esomeprazole 40mg.
treatment during follow-up (𝑝 = 0.003). A statistically
nonsignificant tendency towards a more successful contin-
uation with placebo treatment was found for patients with
less gastrointestinal symptoms (total GSRS score, 𝑝 = 0.07).
The subscore regarding reflux symptoms (heartburn and
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Table 2: Gastrointestinal symptoms at baseline and after 1 year according to randomization group.
Gastrointestinal symptom
rating scale, median (IQR)†
Baseline 1 year
𝑝 value‡Placebo PPI∗ Placebo PPI∗
𝑁 = 85 𝑁 = 86 𝑁 = 69 𝑁 = 79
Total score 2.6 (2.4; 2.8) 2.5 (2.3; 2.7) 1.9 (1.7; 2.1) 1.8 (1.7; 2.0) 0.73
Abdominal pain 2.7 (2.4; 3.0) 2.6 (2.4; 2.8) 2.0 (1.8; 2.3) 1.8 (1.6; 2.0) 0.58
Reflux 3.2 (2.8; 3.5) 3.1 (2.7; 3.4) 1.8 (1.6; 2.0) 1.8 (1.6; 2.0) 0.74
Indigestion 3.1 (2.8; 3.3) 3.0 (2.7; 3.2) 2.2 (2.0; 2.5) 2.2 (1.9; 2.4) 0.83
Diarrhea 2.2 (1.9; 2.5) 1.9 (1.6; 2.1) 1.6 (1.4; 1.8) 1.5 (1.3; 1.7) 0.48
Constipation 2.2 (1.9; 2.5) 2.0 (1.7; 2.3) 1.8 (1.5; 2.0) 1.7 (1.5; 2.0) 0.88
∗Esomeprazole 40mg.
†Gastrointestinal symptom rating scale. Range 1–7. Increasing values reflect increasing symptoms.
‡Between group comparison. Difference in GSRS score at entry versus one year. Conditional linear regression adjusted for GP clusters.
Table 3: Associations with discontinuation in placebo group (𝑛 = 85).
Successful discontinuation
(continuing placebo)
(𝑛 = 23)
Unsuccessful discontinuation
(discontinuing placebo)
(𝑛 = 62)
𝑝 value∗
Age median (IQR), year 58 (48–62) 60 (51–69) 0.81
Male (%) 23% 58% 0.003
Helicobacter pylori-positive, % (95% CI) 29 (12–51) 17 (8–29) 0.24
No nicotine use, % (95% CI) 68 (46–85) 50 (37–63) 0.12
Alcohol use, <21 units/weeks, % (95% CI) 92 (74–99) 92 (82–97) 0.96
Symptom duration, median (10%; 90%)
percentile, year 4 (0–13) 4 (1–14) 0.21
Previous endoscopy, % (95% CI) 40 (21–61) 47 (24–60) 0.58
Previous NSAID/ASA use, % (95% CI) 60 (39–79) 62 (48–74) 0.89
GSRS total, mean (95% CI) 2.5 (2.2–2.8) 2.9 (2.5–3.2) 0.07
GSRS reflux score, mean (95% CI) 3.0 (2.5–3.5) 3.3 (2.9–3.8) 0.29
SF-36 physical health summary score, mean score
(95% CI) 41 (36–46) 43 (40–46) 0.54
SF-36 mental health summary score, mean score
(95% CI) 48 (42–54) 51 (49–54) 0.20
∗
𝐹-test for linear regression.
regurgitation) did, however, show less influence on continued
placebo treatment (𝑝 = 0.29).
4. Discussion
The present study provides estimates from primary care
on the need for continued antisecretory treatment among
long-term users. In a randomised, placebo-controlled trial,
long-term users of antisecretory treatment were randomised
to either continued antisecretory treatment (esomeprazole
40mg) or placebo. We found that 27% of participants
receiving placebo did not stop the trial medication during the
complete follow-up.
To our knowledge, this study was the first nonindustry
initiated drug trial conducted in a primary care setting,
which was GCP monitored by a public GCP unit. The
randomised design and blinding in the design hindered any
contamination between participants in the same practice and
allowed a blinded data analysis. The primary care setting
is important as 90% of antisecretory drugs are prescribed
in primary care [14] and the findings may be applicable to
patients managed in primary care in similar settings.
Recruitment of patients for the study tended to be slower
than expected and only 38% of the coinvestigators (GPs)
recruited participants for the study. No differences were,
however, found between GPs not including participants
compared with active coinvestigators.
Based on register data [15], a large group of persons met
the definition of long-term use of antisecretory treatment
[4], but only a minority of the persons was included in
this particular study. However, the register data do not
provide information about indications for the prescription
of antisecretory medication and some of the persons in the
registers were probably meeting one or more of the exclusion
criteria defined for the study. However, we cannot rule out the
possibility that some of the persons, who were not included,
had already tried to discontinue their antisecretory treatment.
Due to the absence of consensus on the optimal treat-
ment duration, the design of a discontinuation study was
chosen and the discontinuation of trial drug was the primary
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outcome measure. The fluctuation of dyspepsia symptoms
is well known and severity as well as symptoms may vary
in the same patient over time [16]. This may give rise to
reflections on whether disappearance of symptoms due to
the natural history of symptom fluctuation would allow
participants receiving placebo to continue the trial drug.
However, discontinuation of the trial drug largely took place
during the first two months of follow-up and no discontin-
uation occurred during the last six months in the placebo
group.
Rebound acid secretion following discontinuation may
occur [17–20]. In this study, a potential rebound effect
may have been an important factor and would result in
an underestimation of the proportion of participants who
succeeded in a continuation of placebo. Possible tapering
of PPIs would probably be more appropriate than abrupt
termination. However, the study also elucidated that if symp-
toms do not recur within the first 60 days of PPI withdrawal
they are unlikely to recur. No endoscopy was performed
prior to inclusion, which might be a limitation, as patients
with uninvestigated dyspepsia on long-term treatment with
PPI could in principle suffer from erosive esophagitis and
therefore should probably not have withheld treatment.
This is the first placebo-controlled study on discontin-
uation of an acid-suppressive drug in a group of long-term
users, with intervention carried out in primary care, but the
results are in line with those of Bjo¨rnsson et al. [9], who
found that discontinuation was successful in 27% of long-
term users. Their patients had symptom profiles very similar
to those of our patients, but patients were allocated to taper
down or constant dose before discontinuation and placebo
was not introduced.
A number of studies examined discontinuation of PPI
but without inclusion of a placebo group. A recent study
by Murie et al. [21] included patients with a diagnosis
of gastroesophageal reflux disease or functional dyspepsia
for prospective intervention of patient education given at
specialist nurse clinic. PPI was successfully discontinued in
34% and more than half of the patients reduced the PPI
dose. In a study by Krol et al. [22], GPs were randomized to
give usual care or sending a simple information leaflet about
dyspepsia to patients treated with PPI for at least 12 weeks. A
higher discontinuation rate (24%) was demonstrated in the
intervention group, but the difference between groups did not
persist after 20 weeks.
It may be objected that placebo treatment is not equiva-
lent to absence of therapy and that 50–60% of patients with
gastroesophageal reflux disease are satisfied with placebo on
demand [23]. On the other hand, the perception of placebo
is changing [24, 25] and in the present study symptoms
were controlled for more than 6 months on placebo. Finally,
psychological factors are of some importance in heartburn
suffers [26]. Thus, on balance, it seems reasonable to con-
sider stopping use of acid-suppressive drugs in a substantial
number of long-term users without complicated peptic ulcer,
severe oesophagitis, or need for protection against NSAIDs.
Considerable savings could be expected if these results are
applicable to the entire population of long-term users and
future studies should concentrate on delineating factors
predictive of successful discontinuation of proton pump
inhibitors.
We recommend that symptom-based long-term antise-
cretory treatment in general practice should be interrupted by
attempts at discontinuation. In our placebo-controlled study,
nearly one-third of the patients were satisfied with placebo
treatment. One in five patients treated with esomeprazole
had even unsatisfactory symptom control and discontinued
trial medication. Deleterious effects of antisecretory drugs
have been reported [5, 27–30], and unnecessary treatment
may lead to polypharmacy and unnecessary expenses for the
patient and society. Randomised, controlled discontinuation
trials, such as the study presented in this paper, are uncom-
mon, but they may be useful in other areas of medicine (e.g.,
treatment with NSAIDs).
Ethical Approval
The trial was approved by the local scientific ethics committee
and the Danish Data Protection Agency and was carried out
in accordance with the Declaration of Helsinki. The study
was monitored during planning, conduction, and analysis by
the external Good Clinical Practice (GCP) unit at Odense
University Hospital, Denmark.
Disclosure
The entire funding source had no involvement in the study or
in the approval of the paper.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Authors’ Contribution
All investigators contributed to the design, interpretation of
data, and writing of the paper. Jon Eik Zwisler was the prin-
cipal investigator dealing with data collection, management,
and analysis. All authors have read and approved the paper.
Acknowledgments
This study was supported by grants from the Danish College
of General Practitioners (the Lundbeck grant, the PLU Fund,
and theMPUFund), theCounty of Funen (theKAFFund and
the Foundation forMedical Science Research), Clinical Insti-
tute, University of Southern Denmark, Department of Med-
ical Gastroenterology, Odense University Hospital, Institute
of Clinical Medicine, University of Southern Denmark, the
Danish Pharmacy Foundation, the Danish Research Council
of Health Science, the Danish Medical Association, and the
ResearchUnit forGeneral Practice, Odense. AstraZeneca and
DuraScan (Sandoz) supplied most of the medication for the
project.
6 International Journal of Family Medicine
References
[1] P. Haastrup, M. S. Paulsen, J. E. Zwisler et al., “Rapidly
increasing prescribing of proton pump inhibitors in primary
care despite interventions: a nationwide observational study,”
European Journal of General Practice, vol. 20, no. 4, pp. 290–293,
2013.
[2] A. Lødrup, C. Reimer, and P. Bytzer, “Use of antacids, alginates
and proton pump inhibitors: a survey of the general Danish
population using an internet panel,” Scandinavian Journal of
Gastroenterology, vol. 49, no. 9, pp. 1044–1050, 2014.
[3] C. Cahir, T. Fahey, L. Tilson, C. Teljeur, and K. Bennett,
“Proton pump inhibitors: potential cost reductions by applying
prescribing guidelines,” BMC Health Services Research, vol. 12,
no. 1, article 408, 2012.
[4] A. Lassen, J. Hallas, and O. B. S. de Muckadell, “Use of
anti-secretory medication: a population-based cohort study,”
Alimentary Pharmacology&Therapeutics, vol. 20, no. 5, pp. 577–
583, 2004.
[5] A. S. Raghunath, C. O’Moraint, and R. C.McLoughlin, “Review
article: the long-term use of proton-pump inhibitors,” Alimen-
tary Pharmacology and Therapeutics, vol. 22, no. 1, pp. 55–63,
2005.
[6] P.Moayyedi, B. C.Delaney,N.Vakil, D. Forman, andN. J. Talley,
“The efficacy of proton pump inhibitors in nonulcer dyspepsia:
a systematic review and economic analysis,” Gastroenterology,
vol. 127, no. 5, pp. 1329–1337, 2004.
[7] J. Huang, S. K. Lam, P. Malfertheiner, and R. H. Hunt, “Has
education about Helicobacter pylori infection been effective?
Worldwide survey of primary care physicians,” Journal of
Gastroenterology and Hepatology, vol. 18, no. 5, pp. 512–520,
2003.
[8] S. V. Van Zanten, N. Flook, N. J. Talley et al., “One-week acid
suppression trial in uninvestigated dyspepsia patients with epi-
gastric pain or burning to predict response to 8weeks’ treatment
with esomeprazole: a randomized, placebo-controlled study,”
Alimentary Pharmacology & Therapeutics, vol. 26, no. 5, pp.
665–672, 2007.
[9] E. Bjo¨rnsson, H. Abrahamsson, M. Simre´n et al., “Discontin-
uation of proton pump inhibitors in patients on long-term
therapy: a double-blind, placebo-controlled trial,” Alimentary
Pharmacology and Therapeutics, vol. 24, no. 6, pp. 945–954,
2006.
[10] B. Gandek, J. E. Ware Jr., N. K. Aaronson et al., “Tests of data
quality, scaling assumptions, and reliability of the SF-36 in
eleven countries: results from the IQOLA Project,” Journal of
Clinical Epidemiology, vol. 51, no. 11, pp. 1149–1158, 1998.
[11] D. A. Revicki, M.Wood, I. Wiklund, and J. Crawley, “Reliability
and validity of the gastrointestinal symptom rating scale in
patients with gastroesophageal reflux disease,” Quality of Life
Research, vol. 7, no. 1, pp. 75–83, 1998.
[12] P. Bytzer, J. M. Hansen, O. B. Schaffalitzky de Muckadell,
and A. Malchow-Møller, “Predicting endoscopic diagnosis in
the dyspeptic patient. The value of predictive score models,”
Scandinavian Journal of Gastroenterology, vol. 32, no. 2, pp. 118–
125, 1997.
[13] P. C. Gotzsche, “Blinding during data analysis and writing of
manuscripts,” Controlled Clinical Trials, vol. 17, no. 4, pp. 285–
293, 1996.
[14] Annual Statistics, Danish Medicines Agency, 2015, http://dkma
.medstat.dk/.
[15] D. Gaist, H. T. Sørensen, and J. Hallas, “TheDanish prescription
registries,” Danish Medical Bulletin, vol. 44, no. 4, pp. 445–448,
1997.
[16] L. Agre´us, K. Sva¨rdsudd, O. Nyre´n, and G. Tibblin, “Irritable
bowel syndrome and dyspepsia in the general population:
overlap and lack of stability over time,” Gastroenterology, vol.
109, no. 3, pp. 671–680, 1995.
[17] C. Reimer, B. Søndergaard, L. Hilsted, and P. Bytzer, “Proton-
pump inhibitor therapy induces acid-related symptoms in
healthy volunteers after withdrawal of therapy,” Gastroenterol-
ogy, vol. 137, no. 1, pp. 80.e1–87.e1, 2009.
[18] N. G. M. Hunfeld, W. P. Geus, and E. J. Kuipers, “Systematic
review: rebound acid hypersecretion after therapy with proton
pump inhibitors,” Alimentary Pharmacology and Therapeutics,
vol. 25, no. 1, pp. 39–46, 2007.
[19] A. Niklasson, L. Lindstro¨m, M. Simre´n, G. Lindberg, and E.
Bjo¨rnsson, “Dyspeptic symptom development after discontin-
uation of a proton pump inhibitor: a double-blind placebo-
controlled trial,” American Journal of Gastroenterology, vol. 105,
no. 7, pp. 1531–1537, 2010.
[20] A. B. Lodrup, C. Reimer, and P. Bytzer, “Systematic review:
symptoms of rebound acid hypersecretion following proton
pump inhibitor treatment,” Scandinavian Journal of Gastroen-
terology, vol. 48, no. 5, pp. 515–522, 2013.
[21] J. Murie, J. Allen, R. Simmonds, and C. de Wet, “Glad you
brought it up: a patient-centred programme to reduce proton-
pump inhibitor prescribing in generalmedical practice,”Quality
in Primary Care, vol. 20, no. 2, pp. 141–148, 2012.
[22] N. Krol, M. Wensing, F. Haaijer-Ruskamp et al., “Patient-
directed strategy to reduce prescribing for patients with dys-
pepsia in general practice: a randomized trial,” Alimentary
Pharmacology andTherapeutics, vol. 19, no. 8, pp. 917–922, 2004.
[23] T. Lind, T. Havelund, L. Lundell et al., “On demand therapy
with omeprazole for the long-term management of patients
with heartburn without oesophagitis—a placebo-controlled
randomized trial,” Alimentary Pharmacology and Therapeutics,
vol. 13, no. 7, pp. 907–914, 1999.
[24] A. Hro´bjartsson and P. C. Gøtzsche, “Is the placebo powerless?
Update of a systematic review with 52 new randomized trials
comparing placebo with no treatment,” Journal of Internal
Medicine, vol. 256, no. 2, pp. 91–100, 2004.
[25] T. J. Kaptchuk, J. M. Kelley, L. A. Conboy et al., “Components
of placebo effect: randomised controlled trial in patients with
irritable bowel syndrome,” British Medical Journal, vol. 336, no.
7651, pp. 999–1003, 2008.
[26] B. T. Johnston, J. Gunning, and S. A. Lewis, “Health care seeking
by heartburn sufferers is associated with psychosocial factors,”
The American Journal of Gastroenterology, vol. 91, no. 12, pp.
2500–2504, 1996.
[27] Y.-X. Yang, J. D. Lewis, S. Epstein, and D. C. Metz, “Long-term
proton pump inhibitor therapy and risk of hip fracture,” Journal
of the American Medical Association, vol. 296, no. 24, pp. 2947–
2953, 2006.
[28] R. J. F. Laheij, M. C. J. M. Sturkenboom, R.-J. Hassing, J.
Dieleman, B. H. C. Stricker, and J. B. M. J. Jansen, “Risk
of community-acquired pneumonia and use of gastric acid-
suppressive drugs,” Journal of the AmericanMedical Association,
vol. 292, no. 16, pp. 1955–1960, 2004.
International Journal of Family Medicine 7
[29] S. Dial, J. A. C. Delaney, A. N. Barkun, and S. Suissa, “Use
of gastric acid-suppressive agents and the risk of community-
acquired Clostridium difficile-associated disease,” Journal of the
American Medical Association, vol. 294, no. 23, pp. 2989–2995,
2005.
[30] P. Moayyedi and G. I. Leontiadis, “The risks of PPI therapy,”
Nature Reviews Gastroenterology and Hepatology, vol. 9, no. 3,
pp. 132–139, 2012.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
